All patients on the waiting list received 1000 mg of calcium and 400 IE of supplement D daily, and bisphosphonate was given following liver transplant to those patients who got either osteopenia or osteoporosis before transplant. Patients whose BMD decreased following the transplant were also provided bisphosphonate. The striking result of this study was that alendronate combined with calcium and supplement D almost completely prevented further bone loss in the first 4 weeks after LT [liver transplant], the authors state. This is a significant improvement when compared to natural course of bone loss within the first few months after LT as reported in various publications. In addition, sufferers with osteoporosis and osteopenia, which accounted for 72 % of the patients in the scholarly research, remained stable on the alendronate therapy for the first four weeks after transplant and demonstrated considerably improved BMD over the next three years, although generally their BMD didn’t ever reach normal amounts.We are worked up about these results and the enthusiasm of our co-workers, stated Andrew Parsa, MD, PhD, corresponding author of the scholarly study and seat of neurological surgery in Northwestern Memorial Hospital and the Michael J. We are also thinking about the ongoing NCI Alliance trial and the chance never to only advance a new therapy for patients with GBM but to support the development of innovative immunologic and imaging equipment. .. $58M INext Fund established to motivate investment in Indiana life sciences opportunities Capitalizing on the continued strong development of Indiana’s lifestyle sciences industry and an active venture capital market, leaders from BioCrossroads, Eli Lilly and Company, Indiana State Teachers Pension Fund, Indiana University, Purdue University, the University of Notre Dame, Richard M.